Lung cancer research and treatment: global perspectives and strategic calls to action

Authors: Meyer, M.-L. ¹, Peters, S. ², Mok, T.S. ³, Lam, S. ⁴, Yang, P.-C. ⁵, Aggarwal, C. ⁶, Brahmer, J. ⁷, Dziadziuszko, R. ⁸, Felip, E. ⁹, Ferris, A. ¹⁰, Forde, P.M. ¹¹, Gray, J. ¹², Gros, L. ¹³, Halmos, B. ¹⁴, Herbst, R. ¹⁵, Jänne, P.A. ¹⁶, Johnson, B.E. ¹⁷, Kelly, K. ¹⁸, Leighl, N.B. ¹⁹, Liu, S. ²⁰, Lowy, I. ²¹, Marron, T.U. ²², Paz-Ares, L. ²³, Rizvi, N. ²⁴, Rudin, C.M. ²⁵, Shum, E. ²⁶, Stahel, R. ²⁷, Trunova, N. ²⁸, Bunn, P.A. ²⁹, Hirsch, F.R. ^{1, ∗}

Source: In Annals of Oncology December 2024 35(12):1088-1104

Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors

Authors: Lewis, K.D., Peris, K., Sekulic, A., Stratigos, A.J., Dunn, L., Eroglu, Z., Chang, A.L.S., Migden, M.R., Yoo, S.-Y., Mohan, K., Coates, E., Okoye, E., Bowler, T., Baurain, J.-F., Bechter, O., Hauschild, A., Butler, M.O., Hernandez-Aya, L., Licitra, L., Neves, R.I., Ruiz, E.S., Seebach, F., Lowy, I., Goncalves, P., Fury, M.G.

Source: In Annals of Oncology February 2024 35(2):221-228

A-308 - Trial in Progress: A Phase 3 Randomised Study of Low Dose Intralesional Cemiplimab Versus Primary Surgery for Patients with Early-Stage Cutaneous Squamous Cell Carcinoma

Authors: Migden, M. ¹, Ibrahim, S. ², Strasswimmer, J. ³, Zeitouni, N. ⁴, Yoo, S.-Y. ⁵, Seebach, F. ⁵, Lowy, I. ⁵, Cristea, M. ⁵, Fury, M. ⁵

Source: In EJC Skin Cancer 2025 3 Supplement 1

A-685 - A Phase 3 trial of fianlimab + cemiplimab versus pembrolizumab in patients with previously untreated, unresectable, locally advanced or metastatic melanoma

Authors: Hamid, O. ¹, Long, G.V. ², Sznol, M. ³, Smylie, M. ⁴, Fang, F. ⁵, Mani, J. ⁵, Salvati, M. ⁵, Lowy, I. ⁵, Fury, M.G. ⁵, Lewis, K. ⁵

Source: In EJC Skin Cancer 2025 3 Supplement 1

A-684 - A Phase 3 trial of fixed-dose combination of fianlimab + cemiplimab vs relatlimab + nivolumab in patients with unresectable or metastatic melanoma

Authors: Khushalani, N.I. ¹, Kirkwood, J.M. ², McKean, M. ³, Petrella, T.M. ⁴, Mani, J. ⁵, Booth, J. ⁵, Zhang, Z. ⁵, Salvati, M. ⁵, Lowy, I. ⁵, Fury, M.G. ⁵, Lewis, K. ⁵, Manvelian, G. ⁵, Tawbi, H.A. ⁶

Source: In EJC Skin Cancer 2025 3 Supplement 1

A-378 - A Multicentre, Open-Label, Phase 2 Study of Intratumoural Vidutolimod in Combination with Intravenous Nivolumab in Patients with Refractory, Unresectable or Metastatic Melanoma: Clinical and Correlative Results

Authors: Milhem, M. ¹, Kirkwood, J.M. ², Beasley, G. ³, Hu-Lieskovan, S. ⁴, Thomas, S. ⁵, Shoushtari, A. ⁶, Cowey, C.L. ⁷, Izar, B. ⁸, Bhatia, S. ⁹, Naqash, A.R. ¹⁰, Chandra, S. ¹¹, Bao, M. ¹², Tao, W. ¹³, Fiaschi, N. ¹³, Leary, A. ¹³, Chen, J. ¹³, Chio, E. ¹³, Modi, D. ¹³, Booth, J. ¹³, French, C. ¹³, Lowy, I. ¹³, Fury, M. ¹³, Paoluzzi, L. ¹³

Source: In EJC Skin Cancer 2025 3 Supplement 1

A-310 - Fianlimab + cemiplimab in patients with advanced melanoma: Subgroup analyses by blinded independent central review (BICR)

Authors: McKean, M. ¹, Weise, A. ², Papadopoulos, K.P. ³, Crown, J. ⁴, Thomas, S.S. ⁵, Mehnert, J. ⁶, Kaczmar, J. ⁷, Kim, K.B. ⁸, Lakhani, N.J. ⁹, Yushak, M. ¹⁰, Mani, J. ¹¹, Fang, F. ¹¹, Chen, S. ¹¹, Chen, J. ¹¹, Brennan, L. ¹¹, Wang, J. ¹¹, Lowy, I. ¹¹, Salvati, M. ¹¹, Fury, M.G. ¹¹, Lewis, K. ¹¹, Hamid, O. ¹²

Source: In EJC Skin Cancer 2025 3 Supplement 1

A-331 - Phase 2 study of intratumoral vidutolimod in combination with intravenous cemiplimab in patients with selected advanced cancer or metastatic cancer: trial in progress

Authors: Bhatia, S. ¹, Davar, D. ², Thomas, S. ³, Silk, A.W. ⁴, Wu, R.C. ⁵, Ladwa, R. ⁶, Park, S.J. ⁷, Kelly, C.M. ⁸, Wong, D.J. ⁹, Grewal, J. ¹⁰, Vohra, N. ¹¹, Lim, A.M. ¹², Puegero, J. ¹³, Verschraegen, C. ⁵, Zhong, B. ¹⁴, Lowy, I. ¹⁵, Fury, M. ¹⁵, Cristea, M. ¹⁶

Source: In EJC Skin Cancer 2024 2 Supplement 1

A-305 - A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma

Authors: Kaczmar, J. ¹, Papadopoulos, K. ², Ansstas, G. ³, Birnbaum, A. ⁴, Mehnert, J. ⁵, Hamid, O. ⁶, Hughes, B. ⁷, Rabinowits, G. ⁸, Wei, A. ⁹, Yushak, M. ¹⁰, Mani, J. ¹¹, Fang, F. ¹¹, Wang, J. ¹¹, Kroog, G. ¹¹, Salvati, M. ¹¹, Lowy, I. ¹¹, Fury, M. ¹¹, Lakhani, N.J. ¹²

Source: In EJC Skin Cancer 2024 2 Supplement 1

LBA4 Low-dose stereotactic body radiotherapy prior to pre-operative cemiplimab for patients with resectable hepatocellular carcinoma

Authors: Marron, T.U., Hapanowicz, O., Lucas, N., Wu, K., Buckstein, M., Tabrizian, P., Taouli, B., Kim, E., Garcia-Reyes, K., Fiel, M.I., Ward, S., Cohen, N., Hiotis, S., Thanigaimani, P., Hao, Y., Lowy, I., Miller, E.A., Uldrick, T.S., Schwartz, M., Merad, M.

Source: In Immuno-Oncology and Technology December 2023 20 Supplement

127P REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study

Authors: Winer, I.S., O'Cearbhaill, R.E., Bouberhan, S., Hays, J.L., Wenham, R.M., Roque, D.R., Yeku, O.O., Liu, J.F., Wang, B., Yoo, S-Y., Govindraj, S., Zhu, M., Brouwer-Visser, J., Peterman, M.J., Barnes, B., Lowy, I., Knorr, D., Uldrick, T.S., Miller, E.A.

Source: In Immuno-Oncology and Technology December 2023 20 Supplement

41P Phase I analysis of ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer

Authors: Moore, K.N., O'Malley, D., Van Nieuwenhuysen, E., Hamilton, E., O'Cearbhaill, R.E., Yeku, O., Bouberhan, S., Hou, J.Y., Peterman, M., Goncalves, P., Schmidt, T., Yoo, S-Y., Zhu, M., Lowy, I., Rowlands, T., Uldrick, T., Miller, E.A., Liu, J.

Source: In ESMO Open February 2023 8(1) Supplement 1

197TiP First-in-human (FIH) phase I/II study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC)

Authors: Moore, K.N., Bouberhan, S., Hamilton, E., Liu, J., O'Cearbhaill, R.E., O'Malley, D., Papadimitriou, K., Schröder, D., Van Nieuwenhuysen, E., Yoo, S-Y., Peterman, M., Goncalves, P., Schmidt, T., Zhu, M., Lowy, I., Uldrick, T., Miller, E.A.

Source: In Immuno-Oncology and Technology December 2022 16 Supplement 1

168P Liver metastases (mets) and treatment effect of cemiplimab-based therapy: An analysis from three phase III trials (EMPOWER-Lung 1, EMPOWER-Lung 3 part 2, and EMPOWER-Cervical 1)

Authors: Baramidze, A., Gessner, C., Gogishvili, M., Sezer, A., Makharadze, T., Kilickap, S., Gumus, M., Tewari, K.S., Monk, B.J., de Melo, A.C., Oaknin, A., Li, S., Gao, B., Mathias, M.D., Gullo, G., Salvati, M.E., Seebach, F., Lowy, I., Fury, M., Rietschel, P.

Source: In Immuno-Oncology and Technology December 2022 16 Supplement 1

127P Phase I study of fianlimab: A human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced NSCLC

Authors: Cho, B.C., Dy, G., Kim, T.M., Sarker, D., Hamid, O., Williamson, S., Sang-We, K., Hatim, H., Chen, S., Mani, J., Jankovic, V., Paccaly, A.J., Masinde, S., Lowy, I., Brennan, L., Gullo, G.

Source: In Immuno-Oncology and Technology December 2022 16 Supplement 1

P4.07D.03 Phase 2 Peri-Operative Study of Fianlimab+Cemiplimab+Chemotherapy vs Cemiplimab+Chemotherapy in Resectable Early-Stage NSCLC

Authors: Paz-Ares, L., Girard, N., Spira, A., Chaudhry, U., Ghattas, M., Li, S., Salvati, M., Lowy, I., Fury, M.G., Paoluzzi, L.

Source: In Journal of Thoracic Oncology October 2024 19(10) Supplement:S377-S378

OA11.06 Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1

Authors: Kilickap, S., Sezer, A., Özgüroğlu, M., Gumus, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Cicin, I., Fuang, H.G., Kulyaba, Y., Zyuhal, K., Scheusan, R.-I., Baramidze, A., Garassino, M.C., Li, Y., Jia, X., Kaul, M., Perez, J., Seebach, F., Lowy, I., Pouliot, J.-F., Kim, E., Rietschel, P., Magnan, H.

Source: In Journal of Thoracic Oncology October 2024 19(10) Supplement:S35-S35

1384P Efficacy of cemiplimab as monotherapy or in combination with chemotherapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC)

Authors: Sato, Y., Tani, Y., Ishii, H., Katakura, S., Oki, M., Watanabe, Y., Yokoyama, T., Naoki, K., Pouliot, J-F., Paccaly, A.J., Kim, E., Mani, J., Li, S., Lowy, I., Seebach, F., Mathias, M.D., Ikeda, S.

Source: In Annals of Oncology September 2024 35 Supplement 2:S868-S868

1097P Long-term follow-up of advanced melanoma (unresectable/metastatic - aMel) patients (pts) treated with fianlimab (FIAN) + cemiplimab (CEMI): Results from blinded independent central review (BICR) efficacy assessment

Authors: Mckean, M., Weise, A.M., Papadopoulos, K.P., Crown, J.P., Thomas, S.S., Mehnert, J.M., Kaczmar, J., Kim, K.B., Lakhani, N.J., Yushak, M.L., Mani, J., Fang, F., Brennan, L., Lowy, I., Salvati, M.E., Fury, M.G., Lewis, K., Hamid, O.

Source: In Annals of Oncology September 2024 35 Supplement 2:S726-S727

EP10.01-03 A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC

Authors: Drilon, A., Awad, M.M., Camidge, D.R., Forde, P.M., Alexander, M., Gadgeel, S.M., Villaruz, L.C., Perez, J., Navas, T., Daly, C., Patel, S., Li, S., Laughlin, M., Lowy, I., Magnan, H., Rietschel, P.

Source: In Journal of Thoracic Oncology November 2023 18(11) Supplement:S602-S603